

DAVIE60.001APC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
MAR 13 2002  
TECH CENTER 1600/2900  
PATENT

Amdt  
2012  
Linda  
3/26/02

Applicant : Panaccio, M. et al.

Appl. No. : 09/077,574 ✓

Filed : September 24, 1998

For : THERAPEUTIC AND  
DIAGNOSTIC  
COMPOSITIONS

Examiner : Devi, S.

) Group Art Unit 1645

) I hereby certify that this correspondence and all  
) marked attachments are being deposited with  
) the United States Postal Service as first-class  
) mail in an envelope addressed to: Assistant  
) Commissioner for Patents, Washington, D.C.  
) 20231, on

February 27, 2002  
(Date)

Jennifer Haynes, Ph.D., Registration No.:  
48,868

AMENDMENT

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the Office Action mailed from the United States Patent and Trademark Office on August 29, 2001(Paper No. 16), please amend the above-identified patent application as follows:

IN THE SPECIFICATION

On page 21, third paragraph (EXAMPLE 4) starting on line 18 and ending on line 24, please cancel the paragraph and insert:

--A lambda ZAP II™ *L. intracellularis* genomic library was plated on a lawn of *Escherichia coli* XLI-Blue™ (23) cells at a density of 2,000 plaque-forming units (pfu) per 150 mm L-broth agar plate. The library was screened with a rabbit anti-*L. intracellularis* sera using the method described in the Protoblot™ Technical Manual (Promega, WI, USA). Filters were blocked in a buffer containing 10mM Tris HCl, pH8.0, 150mM NaCl, 0.05% Tween 20™, 1% w/w gelatin. Positive plaques identified in a primary screen were picked, replated at a lower density and rescreened until individual positive plaques were identified.--.